In a randomized clinical trial, including normoinsulinemic and non-obese PCOS patients, it was found that rosiglitazone, a PPARγ agonist, significantly reduced testosterone levels, without changing insulin levels [264]. This evidence concerns the gene PPARG and polycystic ovary syndrome.